For select breast cancer patients with complete response to neoadjuvant systemic therapy, radiotherapy alone without breast surgery may be feasible, as no tumor recurrences were observed at 5-year follow-up. ja.ma/426mLaK Henry Kuerer HelenMJohnsonMD Simona F. Shaitelman MD, EdM

Veterans in the U.S. face numerous health care challenges, including limited access to early-phase cancer clinical trials. To bridge this gap, KU Cancer Center and VA Kansas City have formalized a partnership to expand access to clinical trials for veterans: bit.ly/4jERIK3

1st part of #Radiotherapy Series that deep dives into #PORT for #Headneckcancer Thanks to ESTRO and Team led by Profs_Mererid & Vincent with superb colleagues Sue Yom Pierluigi Bonomo Part 2 on delineation otw! Must read for residents! thegreenjournal.com/article/S0167-…

KEYNOTE-689 Update at #AACR25 Neoadjuvant + adjuvant #pembrolizumab in resectable LA-HNSCC ✅ EFS HR: 0.73 (95% CI 0.58–0.92) ✅ Median EFS: 51.8 mo vs 30.4 mo ✅ CPS ≥10 subgroup: HR 0.66 (95% CI 0.49–0.88) ✅ 2-yr EFS: 75% vs 62% ✅ Early & sustained KM curve separation ✅

Wow!! 👇🏼👇🏼 Nonoperative Management of Mismatch Repair–Deficient Tumors ⁦NEJM⁩ nejm.org/doi/full/10.10…

Very useful prospective cohort study with excellent PRO data: ascopubs.org/doi/10.1200/OP… Thanks JCO Oncology Practice for the invitation to discuss palliative radiotherapy for incurable esophageal cancer: ascopubs.org/doi/10.1200/OP…

Caution when abandoning ENI in HNSCC. Very sensible and prudent message by Julian Biau MD, PhD. Excellent debate. #ESTRO25

American Cancer Society Matt Cooperberg Jonathan Evan Shoag 🇮🇱🇺🇸 Andrew Vickers Amer. Urol. Assn. ASCO ASTRO PCF Science Todd 〽️ Morgan, MD Edward Schaeffer, MD, PhD NRG Oncology Veracyte, Inc. Elai Davicioni Joe Biden Amar Kishan National Cancer Institute 15/x Summary: - President Biden’s physician followed the current USPSTF recommendation to not perform PSA screening in men >70yo - However, the USPSTF recommendations are flawed as PCa is common in men >70yo, is often more aggressive, if untreated men are more likely to die of

Chemoradiotherapy and Local Excision vs Total Mesorectal Excision in T2-T3ab, N0, M0 Rectal Cancer: The TAUTEM Randomized Clinical Trial ⁦JAMA Surgery⁩ jamanetwork.com/journals/jamas…

🚨SPRING-01🚨 🔍Locally Advanced Rectal Cancer RCT: 25 Gy x 5 ➡️ CAPOX +- Sintilimab 🔥+ Sintilimab demonstrated: ✅⬆️pCR 59% vs 33% ✅No significant adverse surgical or safety signals Time to explore with organ preserving approaches⁉️ #ASCO25

Check out our multi-center retrospective analysis of ablative 5-fraction SMART (Miami Cancer Institute Research) and 15/25-fraction HART (Memorial Sloan Kettering Cancer Center) for unresectable #pancreaticcancer Marsha Reyngold Kathryn Mittauer, PhD Paul Romesser Adeel K Eileen M O’Reilly mdpi.com/2072-6694/17/1…

Congrats Michael Chuong & team! Between 5 fx MR-guided adaptive vs. 15/25 fx CT-guided RT (all ablative w BED ~100 Gy) in LAPC, results favored 5 fx (LC, late toxicity), but promising in both groups. NRG GI011 permits both regimens (w pref for 5 when feasible) – plz enroll 🙏!

Plenary at the ASTRO AM is stacked with 5 phase III studies 🔹 Breast: RADCOMP (proton vs photon) 🔹 H&N: TORPEdo (proton vs IMRT, Europe) 🔹 Prostate: NRG GU005 🔹 Bladder: BART from @TMCIndia 🔹 Brain mets: METIS (RT +/- TTF) amportal.astro.org/sessions/pl-01…

👵💊 Chemo ≥70y: more harm, no gain 📍 ASTER 70s (Lancet 2025) | Phase III | n=1089 | 🇫🇷🇧🇪 🧬 GGI = 8-gene cell-cycle signature (RT-PCR on FFPE) ➡️ High-risk → randomised ⚖️ Arms • 💉 Chemo (4 cycles) ➡️ HT • 🌿 HT alone 📊 Results (7.8y FU): • 🕗 8-yr OS: 72.7% vs 68.3%

🏥Tislelizumab + lenvatinib + GEMOX for unresectable BTC as conversion ZSAB-TransGOLP The Lancet Oncology ➡️Phase 2, 41 patients, China ➡️85% intrahepatic CCA ✅R0 rate: 63% ✅ORR: 49% ❗️G3-4 TRAE: 49% ❗️G3-4 neutropenia: 34% 👉thelancet.com/journals/lanon… #cancer #oncology #MedX

🚨 Can we convert unresectable BTC to curable? 🩺✨ 📊 Lancet Oncol 2025 | ZSAB-TransGOLP | Phase II (n=41) Unresectable locally advanced biliary tract cancer (BTC) Regimen: 💉 Tislelizumab (PD-1 inhibitor) + 💊 Lenvatinib + 💎 GEMOX → conversion therapy Key results: 🔪

“If future patients knew the real truth about #radiation, they would be less scared about treatment.” [☝️92% of patients tx with breast conservation & 81% who underwent mastectomy for #breastcancer agreed with this] #bcsm #radonc   ☢️ ACS Journal Cancer: acsjournals.onlinelibrary.wiley.com/doi/10.1002/cn…

It’s out!!! 🔥🔥🔥 The PREOPANC-2 is in The Lancet Oncology Neoadjuvant FOLFIRINOX 🤜🤛 Gemcitabine based chemoradiotherapy in resecatble / BR ⚖️ No difference in overall survival 😰 Serious adverse events 40% 👍 Both regimens may be considered thelancet.com/journals/lanon…